Clinical Trials Logo

Eczema clinical trials

View clinical trials related to Eczema.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06311682 Not yet recruiting - Atopic Dermatitis Clinical Trials

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

TRAPEDS 2
Start date: May 24, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections [SC]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life. The trial will last for up to 4 years. There will be visits every 2 weeks for the first year and every 6 weeks thereafter. Some of the visits will be conducted by phone. The study involves two different age groups: children aged 2 to under 12 years and infants aged 6 months to under 2 years. This trial compares tralokinumab +TCS to placebo + TCS for children with moderate-to-severe AD and evaluates tralokinumab + TCS for infants with moderate-to-severe AD. Infants will not receive placebo. All subjects will go through a screening process, which is the first part of the trial and will last up to 4 weeks. During this period, it will be checked if the child or infant meets the criteria to participate in the trial. The children will be randomly assigned to receive tralokinumab + TCS or placebo + TCS for the initial 16 weeks, with the treatment being double-blinded. During the first 16 weeks, children will have a 2 out of 3 chance of getting tralokinumab and a 1 out of 3 chance of getting placebo. Thereafter, all subjects will receive tralokinumab + TCS. The infants will receive tralokinumab + TCS as open-label treatment for the entire treatment period, meaning that the participants will know they are receiving tralokinumab. After stopping treatment, all participants will enter a 4-week safety follow-up period.

NCT ID: NCT06309355 Not yet recruiting - Atopic Dermatitis Clinical Trials

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

Start date: June 2024
Phase: Phase 2
Study type: Interventional

This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic dermatitis

NCT ID: NCT06283550 Not yet recruiting - Chronic Hand Eczema Clinical Trials

Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

Start date: April 2024
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the safety, efficacy and tolerability of abrocitinib in subjects with moderate to severe chronic hand eczema, and its effects on skin biomarkers using a noninvasive method of tape stripping.

NCT ID: NCT06280716 Not yet recruiting - Atopic Dermatitis Clinical Trials

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Start date: May 6, 2024
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.

NCT ID: NCT06277765 Not yet recruiting - Atopic Dermatitis Clinical Trials

Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis

Start date: May 30, 2024
Phase: Phase 3
Study type: Interventional

This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in children patients with moderate-to-severe atopic dermatitis.

NCT ID: NCT06244212 Not yet recruiting - Atopic Dermatitis Clinical Trials

Topical Treatment for Atopic Dermatitis

Start date: April 2024
Phase: N/A
Study type: Interventional

Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. While the issue of adherence is not limited to any particular field of medicine, non-adherence occurs in approximately one-third to one-half of dermatological patients. Non-adherence is of importance as it is a significant cause of treatment failure, resulting in worse quality of life, worse health outcomes, and increased insurance costs.

NCT ID: NCT06239311 Not yet recruiting - Clinical trials for Moderate to Severe Atopic Dermatitis

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

Start date: February 2024
Phase: Phase 3
Study type: Interventional

Atopic dermatitis is an ongoing condition that causes skin irritation, redness, and itchiness. Treatments are usually topical - applied to the skin (e.g., moisturisers or medicated creams) - but a wider variety of systemic treatments (that target the whole body) are needed for those whose condition does not improve with topical treatments. Methotrexate, a drug approved for similar conditions such as arthritis and psoriasis, has been shown to improve atopic dermatitis. This randomised, controlled clinical trial will investigate how effective.

NCT ID: NCT06238817 Not yet recruiting - Atopic Dermatitis Clinical Trials

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

TRuE-AD4
Start date: April 6, 2024
Phase: Phase 3
Study type: Interventional

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.

NCT ID: NCT06224192 Not yet recruiting - Atopic Dermatitis Clinical Trials

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD

ROCKET-Outpost
Start date: April 9, 2024
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.

NCT ID: NCT06216392 Not yet recruiting - Atopic Dermatitis Clinical Trials

Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis

Start date: January 2024
Phase: Phase 3
Study type: Interventional

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of GR1802 injection in comparison to placebo in patients with atopic dermatitis. Patients will receive GR1802 injection or Placebo every 2 Weeks.